EUVIMEDEUVIMED entdecken
Crossref

Potential benefits of aortic valve opening in patients with left ventricular assist devices

Elena Romero Dorta iD, Robert Meyn, Markus Müller iD, Christoph Hoermandinger iD, Felix Schoenrath iD, Volkmar Falk iD, Alexander Meyer iD, Nicolas Merke iD, Evgenij Potapov iD, Johanna Mulzer iD, Jan Knierim iD

Artificial Organs · 2025

DOI: 10.1111/aor.14891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Elena Romero Dorta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Intensive Care, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany. Hauptthemen laut MEDLINE: Heart-Assist Devices, Aortic Valve, Aortic Valve Insufficiency, Heart Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aortic regurgitation (AR) is a well‐known cause of impaired outcome in patients with centrifugal left ventricular assist devices (cfLVADs). The failure of the aortic valve (AV) to open at least intermittently is associated with cusp remodeling, commissural fusion, and ultimately developing AR. Our aim was to characterize patients in whom AV opening (AVO) was preserved 6 months after implantation and identify determinants related to it. Methods and Results We conducted standardized echocardiography and collected clinical and laboratory tests at the outpatient clinic 6 months after implantation. We classified patients into those showing intermittently opening of the AV, every 2–3 beats, or in every cycle (AVO) and those whose AV was continuously closed (NAVO). From the 219 cfLVAD implanted in our center between March 2018 and January 2020, 156 subjects were alive and on the device after 6 months. In 2 of the reviewed echocardiograms, we could not evaluate the AV. 99 patients (64%) showed AVO compared to 55 (36%) with NAVO. The first presented higher mean arterial pressure (84 ± 10 vs. 77 ± 13 mm Hg, p = 0.002), larger LV end‐diastolic diameter (LVEDD 57.5 ± 12 vs. 52.7 ± 13 mm, p = 0.022), a better TAPSE (15 ± 4 vs. 13 ± 4 mm, p = 0.028), and less frequently significant AR than patients with NAVO (moderate/severe AR in 6% vs. in 20%, p = 0.042). In a multiple logistic regression, a lower NYHA Class, a larger LVEDD, and a better LV ejection fraction appeared as significant predictors of AVO. After a median follow‐up of 3.2 years, we found no significant impact on survival stratifying patients by AVO (log‐rank p = 0.53).

Conclusion

AVO was associated with better RV function, lower NYHA Class, and a lower rate of significant AR. This could indicate that AVO should be pursued in LVAD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesAortic ValveAortic Valve InsufficiencyHeart FailureHumansMaleFemaleMiddle AgedEchocardiographyAgedRetrospective StudiesTreatment OutcomeAdult

Stichwörter der Autor:innen

aortic regurgitationaortic valve openingechocardiographyleft ventricular assist devices

Autor:innen und Institutionen

  • Department of Cardiology, Angiology and Intensive Care, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.
  • Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Berlin, Germany.
  • DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
  • Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.
  • Department of Internal Medicine and Cardiology, Sana Paulinenkrankenhaus Berlin, Berlin, Germany.
  • Department of Health Sciences and Technology, Translational Cardiovascular Technology, Eidgenössische Technische Hochschule Zürich, Zurich, Switzerland.

ORCID-Profile: Elena Romero Dorta, Markus Müller, Christoph Hoermandinger, Felix Schoenrath, Volkmar Falk, Alexander Meyer, Nicolas Merke, Evgenij Potapov, Johanna Mulzer, Jan Knierim

Zitieren

APA

Romero Dorta, E., Meyn, R., Müller, M., Hoermandinger, C., Schoenrath, F., Falk, V., Meyer, A., Merke, N., Potapov, E., Mulzer, J., & Knierim, J. (2025). Potential benefits of aortic valve opening in patients with left ventricular assist devices. Artificial Organs. https://doi.org/10.1111/aor.14891

Vancouver

Romero Dorta E, Meyn R, Müller M, Hoermandinger C, Schoenrath F, Falk V, et al. Potential benefits of aortic valve opening in patients with left ventricular assist devices. Artificial Organs. 2025. doi:10.1111/aor.14891

BibTeX
@article{RomeroDorta2025,
  author = {Romero Dorta, Elena and Meyn, Robert and Müller, Markus and Hoermandinger, Christoph and Schoenrath, Felix and Falk, Volkmar and Meyer, Alexander and Merke, Nicolas and Potapov, Evgenij and Mulzer, Johanna and Knierim, Jan},
  title = {Potential benefits of aortic valve opening in patients with left ventricular assist devices},
  journal = {Artificial Organs},
  year = {2025},
  doi = {10.1111/aor.14891}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche